Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: publication (211), journal (168), mag (1), monthly (206)

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description: Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma – Bortezomib (weekly) with daratumumab and dexamethasone Indication • Daratumumab
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf

DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly cycles 1-8) Bortezomib-Daratumumab-Dexamethasone Regimen • Myeloma – DVd SC (weekly cycles 1-8) bortezomib
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles1-8-Bortezomib-Daratumumab-Dexamethasone-Ver1.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description: Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with d
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

DVd(Twice weekly)Daratumumab-Bortezomib-Dexamethasone Cycle 9 onwards

Description: Chemotherapy Protocol Myeloma Bortezomib (twice weekly) Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib (twice weekly) with daratumumab and dexamethasone Note
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdTwice-weeklyDaratumumab-Bortezomib-Dexamethasone-Cycle-9-onwards.pdf

Rituximab (3 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (3 Weekly) Regimen Lymphoma – Rituximab (3 weekly) Indication Non Hodgkin’s Lymphoma in combination with chemotherapy Toxicity
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-3-weekly.pdf

Rituximab SC (8 weekly) Ver 1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (8 weekly) Regimen Lymphoma – Rituximab SC (8 weekly) Indication Maintenance single agent therapy in previously untreated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-8-weekly-Ver-1.pdf

Rituximab SC (12 weekly) Ver1

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB SC (12 weekly) Regimen Lymphoma – Rituximab SC (12 weekly) Indication Maintenance single agent therapy in relapsed / refractory
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-SC-12-weekly-Ver1.pdf

Rituximab (weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (weekly) Regimen Lymphoma – Rituximab (weekly) Indication CD20 positive indolent non Hodgkin’s lymphoma. Toxicity Drug Rituxumab Adverse
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-weekly.pdf

Rituximab (8 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (8 Weekly) Regimen Lymphoma – Rituximab (8 weekly) Indication Non-Hodgkin’s Lymphoma as first-line maintenance therapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-8-weekly.pdf

1 to 10 of 257

Previous 1 2 3 4 5 … Next